FDA Brief

Warning letters Drugs

FDA warning letter to

AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

High riskIssued Jan 29, 2025Posted Feb 18, 2025Center for Drug Evaluation and Research (CDER)

FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

What happened

FDA inspected AmWiner & Raphe Holdings LLC dba rapheGenerics Corp's drug manufacturing facility in Dallas, Texas, from June 20 to August 7, 2024, and reviewed the firm's August 21, 2024 response to the inspection observations. The inspection found missing release testing, incomplete process and equipment qualification, inadequate purified water monitoring, and inadequate identity testing of incoming components including propylene glycol and minoxidil. FDA also reviewed product labeling and the website and found MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH and WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT were new drugs marketed without FDA approval.

What FDA found

  1. The firm released drug batches without adequate laboratory testing to confirm final specifications, including identity and strength of each active ingredient.

    21 CFR 211.165(a)
  2. The firm lacked adequate written production and process control procedures approved by quality control and had not completed equipment and process performance qualification or adequately documented, qualified, maintained, and monitored its purified water system.

    21 CFR 211.100(a)
  3. The firm did not test each incoming component lot for identity and did not validate suppliers’ certificates of analysis; this included propylene glycol and minoxidil, and propylene glycol lacked adequate diethylene glycol and ethylene glycol identity testing.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The firm marketed MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH and WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT as OTC hair grower drugs without the FDA-approved application required for marketing.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. The firm’s quality systems were inadequate.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days describing corrective actions and prevention of recurrence. The letter also requests specific plans and data, including diethylene glycol and ethylene glycol test results within 30 calendar days.

Who should pay attention

  • retailers or brands selling LifeCell hair regrowth products
  • contract manufacturers and testing labs for OTC topical drugs
  • companies sourcing propylene glycol or minoxidil

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk